BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 33667585)

  • 1. Liver SBRT with active motion-compensation results in excellent local control for liver oligometastases: An outcome analysis of a pooled multi-platform patient cohort.
    Stera S; Miebach G; Buergy D; Dreher C; Lohr F; Wurster S; Rödel C; Marcella S; Krug D; Frank A G; Ehmann M; Fleckenstein J; Blanck O; Boda-Heggemann J
    Radiother Oncol; 2021 May; 158():230-236. PubMed ID: 33667585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical results of mean GTV dose optimized robotic guided SBRT for liver metastases.
    Andratschke N; Parys A; Stadtfeld S; Wurster S; Huttenlocher S; Imhoff D; Yildirim M; Rades D; Rödel CM; Dunst J; Hildebrandt G; Blanck O
    Radiat Oncol; 2016 May; 11():74. PubMed ID: 27236333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breathing-motion-compensated robotic guided stereotactic body radiation therapy : Patterns of failure analysis.
    Stera S; Balermpas P; Chan MKH; Huttenlocher S; Wurster S; Keller C; Imhoff D; Rades D; Dunst J; Rödel C; Hildebrandt G; Blanck O
    Strahlenther Onkol; 2018 Feb; 194(2):143-155. PubMed ID: 28875297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Results of Mean GTV Dose Optimized Robotic-Guided Stereotactic Body Radiation Therapy for Lung Tumors.
    Baumann R; Chan MKH; Pyschny F; Stera S; Malzkuhn B; Wurster S; Huttenlocher S; Szücs M; Imhoff D; Keller C; Balermpas P; Rades D; Rödel C; Dunst J; Hildebrandt G; Blanck O
    Front Oncol; 2018; 8():171. PubMed ID: 29868486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The SBRT database initiative of the German Society for Radiation Oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases.
    Andratschke N; Alheid H; Allgäuer M; Becker G; Blanck O; Boda-Heggemann J; Brunner T; Duma M; Gerum S; Guckenberger M; Hildebrandt G; Klement RJ; Lewitzki V; Ostheimer C; Papachristofilou A; Petersen C; Schneider T; Semrau R; Wachter S; Habermehl D
    BMC Cancer; 2018 Mar; 18(1):283. PubMed ID: 29534687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases-A pooled analysis of the German working group "stereotactic radiotherapy".
    Rieber J; Streblow J; Uhlmann L; Flentje M; Duma M; Ernst I; Blanck O; Wittig A; Boda-Heggemann J; Krempien R; Lohaus F; Klass ND; Eble MJ; Imhoff D; Kahl H; Petersen C; Gerum S; Henkenberens C; Adebahr S; Hass P; Schrade E; Wendt TG; Hildebrandt G; Andratschke N; Sterzing F; Guckenberger M
    Lung Cancer; 2016 Jul; 97():51-8. PubMed ID: 27237028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stereotactic Robotic Body Radiotherapy for Patients With Unresectable Hepatic Oligorecurrence.
    Berkovic P; Gulyban A; Nguyen PV; Dechambre D; Martinive P; Jansen N; Lakosi F; Janvary L; Coucke PA
    Clin Colorectal Cancer; 2017 Dec; 16(4):349-357.e1. PubMed ID: 28462852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereotactic Body Radiotherapy (SBRT) for liver metastasis - clinical outcomes from the international multi-institutional RSSearch® Patient Registry.
    Mahadevan A; Blanck O; Lanciano R; Peddada A; Sundararaman S; D'Ambrosio D; Sharma S; Perry D; Kolker J; Davis J
    Radiat Oncol; 2018 Feb; 13(1):26. PubMed ID: 29439707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereotactic body radiation therapy for abdominal and pelvic oligometastases: Dosimetric targets for safe and effective local control.
    Rwigema JM; King C; Wang PC; Kamrava M; Kupelian P; Steinberg ML; Lee P
    Pract Radiat Oncol; 2015; 5(3):e183-e191. PubMed ID: 25413386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Additional chemotherapy improved local control and overall survival after stereotactic body radiation therapy for patients with oligo-recurrence.
    Nakamura M; Hashimoto N; Mayahara H; Uezono H; Harada A; Nishikawa R; Matsuo Y; Kawaguchi H; Nishimura H
    Radiat Oncol; 2018 Apr; 13(1):75. PubMed ID: 29688858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single community-based institutional series of stereotactic body radiation therapy (SBRT) for treatment of liver metastases.
    Anstadt EJ; Shumway R; Colasanto J; Grew D
    J Gastrointest Oncol; 2019 Apr; 10(2):330-338. PubMed ID: 31032102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two-institution results of Stereotactic Body Radiation Therapy (SBRT) for treating adrenal gland metastases from liver cancer.
    Xu B; Zhao X; Chen D; Zhao W; Wang X; Ding C; Yuan Z; Zhang H
    BMC Cancer; 2023 Jan; 23(1):73. PubMed ID: 36681809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereotactic body radiotherapy (SBRT) for adrenal metastases of oligometastatic or oligoprogressive tumor patients.
    König L; Häfner MF; Katayama S; Koerber SA; Tonndorf-Martini E; Bernhardt D; von Nettelbladt B; Weykamp F; Hoegen P; Klüter S; Susko MS; Debus J; Hörner-Rieber J
    Radiat Oncol; 2020 Feb; 15(1):30. PubMed ID: 32019553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lung metastases treated with stereotactic body radiotherapy: the RSSearch® patient Registry's experience.
    Ricco A; Davis J; Rate W; Yang J; Perry D; Pablo J; D'Ambrosio D; Sharma S; Sundararaman S; Kolker J; Creach KM; Lanciano R
    Radiat Oncol; 2017 Feb; 12(1):35. PubMed ID: 28143558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity.
    Franzese C; Bonu ML; Comito T; Clerici E; Loi M; Navarria P; Franceschini D; Pressiani T; Rimassa L; Scorsetti M
    J Cancer Res Clin Oncol; 2020 Sep; 146(9):2289-2297. PubMed ID: 32524292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereotactic Body Radiotherapy (SBRT) for Spinal Metastases: Who Will Benefit the Most from SBRT?
    Park HJ; Kim HJ; Won JH; Lee SC; Chang AR
    Technol Cancer Res Treat; 2015 Apr; 14(2):159-67. PubMed ID: 24502552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medically inoperable peripheral lung cancer treated with stereotactic body radiation therapy.
    Kelley KD; Benninghoff DL; Stein JS; Li JZ; Byrnes RT; Potters L; Knisely JP; Zinkin HD
    Radiat Oncol; 2015 May; 10():120. PubMed ID: 26018408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analyses of the local control of pulmonary Oligometastases after stereotactic body radiotherapy and the impact of local control on survival.
    Yamamoto T; Niibe Y; Aoki M; Shintani T; Yamada K; Kobayashi M; Yamashita H; Ozaki M; Manabe Y; Onishi H; Yahara K; Nishikawa A; Katsui K; Oh RJ; Terahara A; Jingu K
    BMC Cancer; 2020 Oct; 20(1):997. PubMed ID: 33054721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significance of liver metastasis volume in breast cancer patients treated with stereotactic body radiotherapy.
    Oymak E; Guler OC; Onal C
    Strahlenther Onkol; 2022 Mar; 198(3):247-253. PubMed ID: 34477885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial on SBRT for unresectable liver metastases: long-term outcome and prognostic factors of survival after 5 years of follow-up.
    Scorsetti M; Comito T; Clerici E; Franzese C; Tozzi A; Iftode C; Di Brina L; Navarria P; Mancosu P; Reggiori G; Fogliata A; Tomatis S; Torzilli G; Cozzi L
    Radiat Oncol; 2018 Nov; 13(1):234. PubMed ID: 30477560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.